US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Nektar Says Eli Lilly Botched Autoimmune Drug Trials

By Ayden Crosby · August 7, 2023, 7:47 PM EDT

Nektar Therapeutics is accusing Eli Lilly of butchering and delaying clinical trials for a new autoimmune-disease drug the two companies agreed to develop together, claiming the pharma giant ruined the drug's...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Nektar Therapeutics v. Eli Lilly & Co

Case Number

3:23-cv-03943

Court

California Northern

Nature of Suit

Contract: Other

Date Filed

August 07, 2023

Featured Stories

Biggest Rulings For Patent Attys In 2026: A Midyear Report No Photo Available

Dani Kass

The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the d... (more story)

AI Notetakers For Doctors Raise 'Bycatching' Liability Risks No Photo Available

Mark Payne

Busy doctors have embraced AI-powered devices that record patient conversations and generate visit notes. The expansion of ambient not... (more story)

Healthcare Deals This Week: AstraZeneca, Novartis, Vertex No Photo Available

Yeji Jesse Lee

Despite a short week, healthcare dealmakers were busy at work, as Law360 counted at least four billion-dollar transactions involving n... (more story)